Oxurion NV Logo

Oxurion NV

OXUR | BR

Overview

Corporate Details

ISIN(s):
BE0974487192
LEI:
549300VWY8KVDFKLDM59
Country:
Belgium
Address:
Gaston Geenslaan 1, 3001 Heverlee
Sector:
Health Care
Industry:
Biotechnology

Description

Oxurion is on a mission to transform the treatment of retinal disorders, including the development of THR-149, its novel therapeutic for the treatment of DME. Oxurion is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people worldwide. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA, and is listed on Euronext Brussels under the symbol OXUR.

Social Media

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-25 18:00
Declaration of Voting Results & Voting Rights Announcements
OXUR-PR_Voting-rights-ENG_20250725.pdf
English 281.3 KB
2025-07-25 18:00
Declaration of Voting Results & Voting Rights Announcements
OXUR-PR_Voting-rights-NED_20250725.pdf
Dutch 405.0 KB
2025-07-24 18:00
Declaration of Voting Results & Voting Rights Announcements
OXUR-PR_Voting-rights-ENG_20250724.pdf
English 283.7 KB
2025-07-24 18:00
Declaration of Voting Results & Voting Rights Announcements
OXUR-PR_Voting-rights-NED_20250724.pdf
Dutch 407.6 KB
2025-07-22 18:00
Regulatory News Service
OXUR-Transparency-Notification-EN-20250722.pdf
English 353.3 KB
2025-07-22 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250722.pdf
Dutch 376.5 KB
2025-07-22 08:30
Capital/Financing Update
OXURION_PR_Allocation-Crypto_20250722_EN_exe.pdf
English 299.5 KB
2025-07-22 08:30
Inside Information Statement
OXURION_PR_Allocation-Crypto_20250722_FR_exe.pdf
French 249.9 KB
2025-07-22 08:30
Inside Information Statement
OXURION_PR_Allocation-Crypto_20250722_NL_exe.pdf
Dutch 329.0 KB
2025-07-17 08:30
Declaration of Voting Results & Voting Rights Announcements
ANNEX-Dilution-Table-_-Oxurion.pdf
English 387.4 KB
2025-07-17 08:30
Regulatory News Service
OXURION_PR_Axiodis_FinancementClosing_EN-1.pdf
English 212.0 KB
2025-07-17 08:30
Regulatory News Service
OXURION_PR_Axiodis_FinancementClosing_FR-1.pdf
French 150.6 KB
2025-07-17 08:30
Regulatory News Service
OXURION_PR_Axiodis_FinancementClosing_NL-1.pdf
Dutch 199.9 KB
2025-07-04 18:00
Major Shareholding Notification
OXUR-PR_Voting-rights-ENG_20250704.pdf
English 282.0 KB
2025-07-04 18:00
Major Shareholding Notification
OXUR-PR_Voting-rights-NED_20250704.pdf
Dutch 399.8 KB

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-07 Bareldam SA Close relation Buy 1,180,555 1,700,000.00 EUR
2021-09-30 Lavinia D. Clay 2009 Revocable Trust Close relation Other 2,766,337 5,601,002.52 EUR

Peer Companies

Company Country Ticker View
1NKEMIA Logo 1NKEMIA Spain IKM
2cureX AB Logo 2cureX AB Sweden 2CUREX
4SC AG Logo 4SC AG Germany VSC
Abera Bioscience AB Logo Abera Bioscience AB Sweden ABERA
ABIONYX Pharma Logo ABIONYX Pharma France ABNX
Abliva Logo Abliva Sweden ABLI
AB Science Logo AB Science France AB
Acticor Biotech Logo Acticor Biotech France ALACT
Active Biotech Logo Active Biotech Sweden ACTI
AcuCort AB Logo AcuCort AB Sweden ACUC